ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

What's Up With These Ridiculous Stock Gains?

Steve Reitmeister didn't want me to tell you this. He felt that one strategy's performance stands out so much that... Read on >>

Quote:

Search for Ticker

Free Membership

Search:

RDEA: Ardea Biosciences Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ARDEA BIOSCIENCES INC (NASD)
RDEA	14.47	0.45	(3.21%)	Vol. 71,783	15:59 ET

IntraBiotics Pharmaceuticals, Inc. develops and intends to commercialize new antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. The company obtained statistically significant data from human clinical trials that test for preliminary safety and efficacy that indicate each of the products are well tolerated and support further efficacy trials. The new antibiotics may solve medical problems for patients who have few or no satisfactory alternatives.

General Information

ARDEA BIOSCIENC

4939 Directors Place San Diego, CA 92121 Phone: 858- 652-6500 Fax: 858-652-0760 Web: www.ardeabiosciences.com Email: investorcenter.ardeabio.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/05/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	14.02
52 Week High	21.35
52 Week Low	7.22
Beta	0.99
20 Day Moving Average	69,960.35
Target Price Consensus	22.9

% Price Change
4 Week	-7.51
12 Week	-23.83
YTD	14.29

% Price Change Relative to S&P 500
4 Week	-8.50
12 Week	-28.19
YTD	-5.41

Share Information
Shares Outstanding (millions)	18.29
Market Capitalization (millions)	250.25
Short Ratio	23.94
Last Split Date	04/11/2003

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.30
Current Year EPS Consensus Estimate	-1.74
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/05/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.50
30 Days Ago	1.50
60 Days Ago	1.50
90 Days Ago	1.50

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	86.32%
vs. Previous Quarter	70.45%

Sales Growth
vs. Previous Year	-%
vs. Previous Quarter:	66.35%

Price Ratios
Price/Book	8.55
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-103.43
06/30/09	-146.44
03/31/09	-157.69

ROA
09/30/09	-60.70
06/30/09	-90.33
03/31/09	-120.24

Current Ratio
09/30/09	-
06/30/09	1.78
03/31/09	5.01

Quick Ratio
09/30/09	-
06/30/09	1.78
03/31/09	5.01

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-
06/30/09	-627.25
03/31/09	-96,863.64

Pre-Tax Margin
09/30/09	-
06/30/09	-627.25
03/31/09	-96,863.64

Book Value
09/30/09	-
06/30/09	1.60
03/31/09	1.87

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-
06/30/09	0.17
03/31/09	0.16

Debt to Capital
09/30/09	-
06/30/09	14.30
03/31/09	14.06


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research